Romidepsin
Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome
National Cancer Institute (NCI)Small moleculePhase 3Active
B
63/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 50/ 100
- Competitive Position
- 89/ 100
Competitive context
13 Active assets in the Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Cytosin-Arabinosid National Cancer Institute (NCI) | Phase 3 | BB |
Daunorubicin National Cancer Institute (NCI) | Phase 3 | BB |
Decitabine National Cancer Institute (NCI) | Phase 3 | BB |
Cediranib University of Southern California | Phase 3 | BB |
Cyclophosphamide City of Hope Medical Center | Phase 3 | BB |
View all 28 →
Same molecule, other indications
Romidepsin is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →